We would love to hear your thoughts about our site and services, please take our survey here.
Exactly that! Balooo
Let’s see how any derampers can turn that into a neg. IMHO this is a fantastic opportunity with plenty of potential. What a great find Mark , big thumbs up to you.
Anyone know any good ramping songs?
Is dotted Ts crossed not long now for the news flow to start, looks like it already has started behind the scenes plenty of buyers lining up not many sellers. Next week will be mega when Suzy let’s the cat out the bag. Onwards and upwards from here GLALTHS.
On what we have, Massive potential
https://www.researchgate.net/publication/352914459_Abstract_1010_A_study_of_combinatorial_growth_inhibition_cell_death_and_DNA_damage_repair_caused_by_CHK1_inhibitor_SRA737_and_WEE1_inhibitor_adavosertib_in_TP53_mutated_cell_lines
Sar. Com also down. Wonder if it’s a sign lol
http://www.sareum.com/
Someone put the schedule up on Twitter, hard to look at on my phone, not seen Sareums slot.
https://twitter.com/andrewe_dunn/status/1611019680612753408?s=46&t=0NssPuGgCpTy6BxiGo6MoA
Free registration for live stream from endpoint, might be something, might be nothing.
https://jpm23.endpts.com/?source=eblast20230108
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/a0f74126-755d-487c-b65c-51d21124fec0
UK government is partnering with German Covid-19 vaccine maker BioNTech to enrol up to 10,000 patients in clinical trials for cutting-edge cancer treatments.
BioNTech, which partnered with US pharmaceutical group Pfizer to develop a Covid jab that was the world’s bestselling by revenue, said on Friday that it would open a research and development centre with 75 staff in Cambridge.
It added that it would open an office in London at the same time, and may later consider investing in manufacturing in the UK.
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/a0f74126-755d-487c-b65c-51d21124fec0
The company is developing personalised cancer vaccines, which it hopes will harness patients’ immune systems to tackle their tumours. The so-called vaccines are tailored to an individual tumour’s genetic code.
Ugur Sahin, BioNTech’s co-founder and chief executive, said the investment to meet the pledge of enrolling 10,000 patients by 2030 would be “huge” but that he could not yet put an exact number on it.
Steve Barclay, the health secretary, said UK patients could possibly participate in the trial from as early as September.
“This agreement builds on this government’s promise to increase research and development spending to £20bn per year,” he said, adding that it “demonstrates the UK remains one of the most attractive places in the world for innovative companies to invest in research”.
The UK last year signed a £1bn deal with Moderna, another Covid vaccine maker, to establish the first manufacturing centre for shots using messengerRNA, which teaches the immune system to recognise pathogens through a genetic code.
Özlem Türeci, BioNTech’s co-founder and chief medical officer, said the UK was an “obvious” choice for the clinical trials because of its “exceptionally agile” regulator, the NHS’s ability to recruit participants and its expertise in genomics.
https://www.ft.com/content/a0f74126-755d-487c-b65c-51d21124fec0
https://www.jpmorgan.com/solutions/cib/insights/health-care-conference
Our Chairman Stephen Parker will be attending the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, from 9-12 January.
At Sareum Ltd we are focused on advancing our internal programmes on distinct dual tyrosine kinase 2 (#TYK2) / Janus kinase 1 (#JAK1) inhibitors into clinical development as potential new therapies for autoimmune diseases, respiratory symptoms arising from viral infections and cancer immunotherapy.
Stephen would be delighted to meet anyone who would like to learn more about Sareum, so please get in contact if you would like to meet with him.
#JPM2023 #Conference #Healthcare
Gropelad you wished ha ha it was .. 30 ish when you ramped boil. As if anyone listen to a prover porkie teller.
“The unexpected bonus is getting out for a while and picking up some baron oil (boil) recoup losses. Big announcement on or before 26th”
You said that on the 20th a look what happen. Your locked in there and here great bit of trading that lad Lol.